Immune System Diseases

All Conditions

Neoplasms

Symptoms and General Pathology

Skin and Connective Tissue Diseases

Infections

Respiratory Tract (Lung and Bronchial) Diseases

Heart and Blood Diseases

Rare Diseases

Autoimmune Diseases

Neoplasm Metastasis

Scleroderma, Systemic

Scleroderma, Diffuse

Pain

Respiratory Tract Infections

Raynaud Disease

Neoplastic Processes

Connective Tissue Diseases

Skin Diseases

Vascular Diseases

Livedoid Vasculopathy

Thrombosis

Embolism

Embolism and Thrombosis

Peripheral Arterial Disease

Peripheral Vascular Diseases

Skin Diseases, Vascular

Systemic Scleroderma

Vasodilator Agents

All Drugs and Chemicals

Nitroglycerin

MQX-503

Leslie Klaff, MD

The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.

The Purpose of this clinical study is to determine, in a controlled fashion, the response to two dosage strengths of a topical gel formulation of Nitroglycerin, MQX-503, in the determination of changes in finger blood flow and skin temperature in the fingers of patients with moderate to severe primary Raynaud's phenomenon and with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma. The dosage strength response in the treatment of the symptoms (pain, tingling, numbness) will also be monitored.

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon

MediQuest Therapeutics

Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.

Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.

Topical AmphiMatrix

Jan Ohrstrom, PhD

The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.

The purpose of this clinical study is to determine, in a controlled fashion, the ability of a topical formulation of Nitroglycerin, MQX-503, to improve the patient's health assessment as indicated by patient and physician assessments, decrease the frequency of Raynaud's events, decrease the duration of Raynaud's events, and decrease the symptoms (pain, tingling, numbness) in the fingers of Raynaud's patients. The study will include patients with moderate to severe primary Raynaud's Phenomenon (RP) and with moderate to severe Raynaud's Phenomenon secondary to autoimmune diseases, such as scleroderma.

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon

Fred Dechow/President and CEO

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon	NCT00378521	Raynaud's Disea... Raynaud's Disea... Raynaud's Disea...	MQX-503	18 Years - 75 Years	MediQuest Therapeutics
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon	NCT00577304	Raynaud's Disea... Raynaud's Disea... Raynaud's Disea...	Nitroglycerin Topical AmphiMa...	15 Years - 70 Years	MediQuest Therapeutics
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon	NCT00577304	Raynaud's Disea... Raynaud's Disea... Raynaud's Disea...	Nitroglycerin Topical AmphiMa...	15 Years - 70 Years	MediQuest Therapeutics
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon	NCT00577304	Raynaud's Disea... Raynaud's Disea... Raynaud's Disea...	Nitroglycerin Topical AmphiMa...	15 Years - 70 Years	MediQuest Therapeutics

Spots Global Cancer Trial Database for raynaud's disease secondary to scleroderma